News
Bevacizumab Biosimilar Alymsys Now Available
Alymsys is a vascular endothelial growth factor inhibitor.
Your search for bevacizumab returned 12 results
News
Bevacizumab Biosimilar Alymsys Gets FDA Approval
The approval was based on data demonstrating that the biosimilar product and the reference product were highly similar, and that there were no clinically meaningful differences between the agents.
News
Bevacizumab Biosimilar Vegzelma Gets FDA Approval
Vegzelma is a vascular endothelial growth factor inhibitor.
News
Immunotherapy Regimen Approved for Hepatocellular Carcinoma
The FDA has approved Tecentriq® in combination with Avastin® for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.
News
Biosimilar Zirabev Gets FDA Approval for 5 Types of Cancer
The FDA has approved Zirabev (bevacizumab-bvzr; Pfizer), a biosimilar to Avastin (bevacizumab; Genentech).
Drugs in the Pipeline
Immunotherapy Combo Reduces Risk of Cancer Recurrence in Early-Stage Liver Cancer
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
News
Keytruda Approved as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer
The approval was based on data from the phase 3 KEYNOTE-826 trial.
Generics News
Pfizer Announces Launch of Three Biosimilar Cancer Treatments
Pfizer announced the launch of 3 new biosimilars: Zirabev (bevacizumab-bvzr), Ruxience (rituximab-pvvr) and Trazimera (trastuzumab-qyyp). Zirabev, a biosimilar to Avastin (bevacizumab; Genentech), is available for the treatment of 5 types of cancer: metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer; recurrent glioblastoma; metastatic renal cell carcinoma; and persistent, recurrent…
Drugs in the Pipeline
Tisotumab Vedotin Under Review for Recurrent or Metastatic Cervical Cancer
Tisotumab vedotin is an investigational antibody-drug conjugate targeted to tissue factor.
News
Mirvetuximab Soravtansine Data Lacking for FDA’s Accelerated Approval in Ovarian CA
The Food and Drug Administration (FDA) has recommended that ImmunoGen, Inc. conduct a new phase 3 randomized trial to evaluate the safety and efficacy of mirvetuximab soravtansine (IMGN853) in patients with high folate receptor alpha (FRα)-positive, platinum-resistant ovarian cancer.
